<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02325518</url>
  </required_header>
  <id_info>
    <org_study_id>ALJ-P2014-1</org_study_id>
    <secondary_id>UMIN000017569</secondary_id>
    <nct_id>NCT02325518</nct_id>
  </id_info>
  <brief_title>Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution</brief_title>
  <official_title>The Efficacy and Safety of Brinzolamide 1%/Timolol 0.5% Fixed Combination Versus Dorzolamide 1%/Timolol 0.5% in Patients With Open-Angle Glaucoma and Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon, a Novartis Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate AZORGA® Ophthalmic Suspension compared to COSOPT®
      Ophthalmic Solution for IOP-lowering efficacy in subjects with open-angle glaucoma or ocular
      hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After the screening examination, subjects were enrolled in the study and moved into the
      observation period. During the observation period, prostaglandin-analog (PGA) monotherapy was
      applied. After the observation period of 4 weeks or more, the baseline examination was
      performed. Subjects were then randomized and moved into the treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Least Squares Mean Change From Baseline in Intraocular Pressure (IOP) at 11 AM</measure>
    <time_frame>Baseline (Day 0), Week 4, Week 8 at 11 AM</time_frame>
    <description>IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in millimeters of mercury (mmHg). Data from 4 and 8 weeks at 11 AM were pooled, and a negative change indicates an improvement. One eye (target eye) was used for the analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Least Squares Mean Change From Baseline in IOP at 9 AM</measure>
    <time_frame>Baseline (Day 0), Week 4, Week 8 at 9 AM</time_frame>
    <description>IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in millimeters of mercury (mmHg). Data from 4 and 8 weeks at 9 AM were pooled, and a negative change indicates an improvement. One eye (target eye) was used for the analysis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">218</enrollment>
  <condition>Open-Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>BRI/TIM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension, 1 drop in each eye twice daily, and habitual PGA monotherapy, 1 drop in each eye once daily for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DOR/TIM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution, 1 drop in each eye twice daily, and habitual PGA monotherapy, 1 drop in each eye once daily for 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension</intervention_name>
    <arm_group_label>BRI/TIM</arm_group_label>
    <other_name>AZORGA®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution</intervention_name>
    <arm_group_label>DOR/TIM</arm_group_label>
    <other_name>COSOPT®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subject's habitual PGA monotherapy</intervention_name>
    <arm_group_label>BRI/TIM</arm_group_label>
    <arm_group_label>DOR/TIM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Understand the nature of the study and sign informed consent.

          -  Diagnosis of open angle glaucoma or ocular hypertension.

          -  Currently on PGA monotherapy or PGA + alpha-1/beta blocker or PGA + alpha-2 agonist at
             screening visit, and allowed to instill only PGA for 4 weeks until the baseline visit.

          -  Intraocular pressure (IOP) ≥ 15 mmHg (at least one same eye) at the baseline visit.

          -  Other protocol-specified inclusion criteria may apply.

        Exclusion Criteria:

          -  History of bronchial asthma, bronchospasm, or serious chronic obstruction pulmonary
             disease.

          -  Uncontrolled heart failure, sinus bradycardia, A-V block (II, III grade), cardiogenic
             shock, right heart failure due to pulmonary hypertension or congestive heart failure.

          -  History of hypersensitivity to any of the excipients of the study medications.

          -  Severe renal function disorders, diabetic ketoacidosis and metabolic acidosis,
             uncontrolled diabetes, or hepatic disorders.

          -  Corneal disorder or history of chronic, recurrent or current severe inflammatory eye
             disease in either eye.

          -  History of ocular trauma in either eye within 6 months prior to the screening
             examination.

          -  Ocular infection or ocular inflammation in either eye.

          -  History of or current clinically significant or progressive retinal disease in either
             eye.

          -  Intraocular surgery in either eye within 6 months prior to the screening examination.

          -  Ocular laser surgery in either eye within 3 months prior to the screening examination.

          -  Any abnormality preventing reliable applanation tonometry of either eye.

          -  Best-corrected visual acuity (BCVA) worse than 0.2 score (decimal visual acuity) in
             either eye.

          -  Severe visual field loss in either eye.

          -  Use of prohibited medication, as specified in the protocol.

          -  Pregnant, lactating, or intending to become pregnant during the study period.

          -  Currently on therapy or have been on therapy with another investigational agent within
             30 days prior to the screening examination.

          -  History of or current evidence of a severe illness or any other condition which would
             make the subject, in the opinion of the investigator, unsuitable for the study.

          -  Other protocol-specified exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical and Regulatory Affairs</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Japan, Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Contact Alcon Japan Ltd. for Trial Locations</name>
      <address>
        <city>Tokyo</city>
        <zip>107-0052</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2014</study_first_submitted>
  <study_first_submitted_qc>December 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2014</study_first_posted>
  <results_first_submitted>October 13, 2016</results_first_submitted>
  <results_first_submitted_qc>October 13, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 8, 2016</results_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Open-angle glaucoma (OAG)</keyword>
  <keyword>Ocular hypertension (OHT)</keyword>
  <keyword>AZORGA®</keyword>
  <keyword>COSOPT®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Dorzolamide</mesh_term>
    <mesh_term>Maleic acid</mesh_term>
    <mesh_term>Brinzolamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from 26 study sites in Japan.</recruitment_details>
      <pre_assignment_details>Of the 218 enrolled, 6 subjects withdrew informed consent and 11 were exited as screen failures prior to randomization. This reporting group includes all randomized subjects (201).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>BRI/TIM</title>
          <description>Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension, 1 drop in each eye twice daily, and habitual prostaglandin-analog (PGA) monotherapy, 1 drop in each eye once daily for 8 weeks.</description>
        </group>
        <group group_id="P2">
          <title>DOR/TIM</title>
          <description>Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution, 1 drop in each eye twice daily, and habitual PGA monotherapy, 1 drop in each eye once daily for 8 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="98"/>
                <participants group_id="P2" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Per Protocol Set (PPS)</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This analysis population includes all randomized subjects who received study medication and completed at least 1 scheduled on-therapy study visit (Full Analysis Set).</population>
      <group_list>
        <group group_id="B1">
          <title>BRI/TIM</title>
          <description>Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension, 1 drop in each eye twice daily, and habitual PGA monotherapy, 1 drop in each eye once daily for 8 weeks.</description>
        </group>
        <group group_id="B2">
          <title>DOR/TIM</title>
          <description>Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution, 1 drop in each eye twice daily, and habitual PGA monotherapy, 1 drop in each eye once daily for 8 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="98"/>
            <count group_id="B2" value="101"/>
            <count group_id="B3" value="199"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.1" spread="11.8"/>
                    <measurement group_id="B2" value="64.4" spread="12.3"/>
                    <measurement group_id="B3" value="63.7" spread="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Least Squares Mean Change From Baseline in Intraocular Pressure (IOP) at 11 AM</title>
        <description>IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in millimeters of mercury (mmHg). Data from 4 and 8 weeks at 11 AM were pooled, and a negative change indicates an improvement. One eye (target eye) was used for the analysis.</description>
        <time_frame>Baseline (Day 0), Week 4, Week 8 at 11 AM</time_frame>
        <population>This analysis population includes all subjects who received study medication and met inclusion/exclusion criteria prior to randomization (Per Protocol Set).</population>
        <group_list>
          <group group_id="O1">
            <title>BRI/TIM</title>
            <description>Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension, 1 drop in each eye twice daily, and habitual PGA monotherapy, 1 drop in each eye once daily for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DOR/TIM</title>
            <description>Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution, 1 drop in each eye twice daily, and habitual PGA monotherapy, 1 drop in each eye once daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares Mean Change From Baseline in Intraocular Pressure (IOP) at 11 AM</title>
          <description>IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in millimeters of mercury (mmHg). Data from 4 and 8 weeks at 11 AM were pooled, and a negative change indicates an improvement. One eye (target eye) was used for the analysis.</description>
          <population>This analysis population includes all subjects who received study medication and met inclusion/exclusion criteria prior to randomization (Per Protocol Set).</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.0" lower_limit="16.6" upper_limit="17.3"/>
                    <measurement group_id="O2" value="17.0" lower_limit="16.6" upper_limit="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean change pooled over Week 4 and Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" lower_limit="-3.6" upper_limit="-2.9"/>
                    <measurement group_id="O2" value="-3.4" lower_limit="-3.7" upper_limit="-3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Least Squares Mean Change From Baseline in IOP at 9 AM</title>
        <description>IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in millimeters of mercury (mmHg). Data from 4 and 8 weeks at 9 AM were pooled, and a negative change indicates an improvement. One eye (target eye) was used for the analysis.</description>
        <time_frame>Baseline (Day 0), Week 4, Week 8 at 9 AM</time_frame>
        <population>Per Protocol Set (PPS)</population>
        <group_list>
          <group group_id="O1">
            <title>BRI/TIM</title>
            <description>Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension, 1 drop in each eye twice daily, and habitual PGA monotherapy, 1 drop in each eye once daily for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>DOR/TIM</title>
            <description>Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution, 1 drop in each eye twice daily, and habitual PGA monotherapy, 1 drop in each eye once daily for 8 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Least Squares Mean Change From Baseline in IOP at 9 AM</title>
          <description>IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in millimeters of mercury (mmHg). Data from 4 and 8 weeks at 9 AM were pooled, and a negative change indicates an improvement. One eye (target eye) was used for the analysis.</description>
          <population>Per Protocol Set (PPS)</population>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" lower_limit="17.1" upper_limit="17.8"/>
                    <measurement group_id="O2" value="17.3" lower_limit="17.0" upper_limit="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Pool (Week 4, Week 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" lower_limit="-3.6" upper_limit="-2.9"/>
                    <measurement group_id="O2" value="-2.9" lower_limit="-3.2" upper_limit="-2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were collected from time of informed consent throughout the duration of a subject’s participation in the study (up to 8 weeks). Ocular adverse events are presented for both study eye and non-study eye combined. AEs are reported as pretreatment and treatment-emergent. This analysis population includes all subjects who received study medication (Safety Analysis Set).</time_frame>
      <desc>An AE was defined as all medically undesirable or unintended diseases or symptoms that occur in subjects who receive study medication regardless of the causal relationship. Reports of AEs were obtained through solicited and spontaneous comments from the subjects and through observations by the Investigator as outlined in the study protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pretreatment</title>
          <description>All subjects who consented to participate in the study prior to the initiation of study treatment</description>
        </group>
        <group group_id="E2">
          <title>BRI/TIM</title>
          <description>Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension, 1 drop in each eye twice daily, and habitual PGA monotherapy, 1 drop in each eye once daily for 8 weeks.</description>
        </group>
        <group group_id="E3">
          <title>DOR/TIM</title>
          <description>Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution, 1 drop in each eye twice daily, and habitual PGA monotherapy, 1 drop in each eye once daily for 8 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA/J (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA/J (18.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="218"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="98"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor reserves the right of prior review of any publication or presentation of information related to the study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Novartis Pharma KK</name_or_title>
      <organization>Alcon, A Novartis Division</organization>
      <phone>1-888-451-3937</phone>
      <email>alcon.medinfo@alcon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

